"Although no one at the company can go on record publicly for the same reasons we mentioned, we have confirmed to the best of our abilities and based on candid interviews with multiple sources, that Positron has partnered with Covidien (NYSE:COV). In addition, our sources tell us that they are also in the process of aligning with other big board companies for some very important strategic partnerships on the pharmaceutical side of the business.Furthermore, it's worth considering that any one of these strategic partners may choose to take a position in or even outright buy the company; especially once the new network of automated imaging drug dispensing machines is set up."
And - this still doesn't make sense ... "Look up IMGG and you'll find a company that traded at close to $2 per share this year based on only "half the promise" that POSC offers today. That company has submitted for FDA approvals several times and still have no clearance, yet they still trade today at nearly fifty cents per share."
News 
Market Data 
Discover 
